Lancet Diabetes Endocrinol: Gospel for Weight Loss People!

With the worldwide obesity epidemic, obesity is gradually becoming a global health problem

With the worldwide obesity epidemic, obesity is gradually becoming a global health problem

Overweight and obesity are major risk factors for type 2 diabetes, cardiovascular disease and cancer

^{Although a BMI ≥ 25 Kg/m 2} is required to diagnose obesity , a BMI ≥ 27 Kg/m ² is considered an appropriate threshold for weight management with investigational drugs because cardiovascular risk factors and mortality appear to be above this threshold in East Asian populations

Glp-1 receptor agonists are effective in lowering glycated hemoglobin and reducing body weight in patients with type 2 diabetes

Methods: This randomized, double-blind, double-dummy, placebo-controlled Phase 3a superiority trial was conducted in 28 outpatient clinics in Japan and South Korea

Methods: This randomized, double-blind, double-dummy, placebo-controlled Phase 3a superiority trial was conducted in 28 outpatient clinics in Japan and South Korea

 

 

Research result:

Research result:

Between January 21, 2019, and June 4, 2019, 437 subjects were screened, of whom 401 were randomized to semaglutide 2 4 mg (n=199), semaglutide Gglutide 1 7 mg (n=101) or placebo (n=101) and included in the intention-to-treat analysis;

Between January 21, 2019, and June 4, 2019, 437 subjects were screened, of whom 401 were randomized to semaglutide 2 4 mg (n=199), semaglutide Gglutide 1 7 mg (n=101) or placebo (n=101) and included in the intention-to-treat analysis;

The mean weight change from baseline to 68 weeks in the semaglutide 2.

The mean weight change from baseline to 68 weeks in the semaglutide 2.

At 68 weeks, the semaglutide 2.

Abdominal visceral fat area was reduced by 40.

Adverse events were reported by 171 of 199 participants (86%) in the semaglutide 2.

Gastrointestinal disturbances occurred in 118 (59%) of 199 subjects in the semaglutide 2.

Adverse events leading to discontinuation of the investigational product occurred in 5 of 199 participants (3%) in the semaglutide 2.

Compared with placebo, obese adults from East Asia, with and without type 2 diabetes, who received semaglutide 2.

Source: Kadowaki T, Isendahl J, Khalid U, et al.

leave a message here